enCore Energy (EU) Stock Nosedives Amid Financial Reporting Concerns and Leadership Shakeup - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 12, 2025) - enCore Energy Corp. (NASDAQ: EU), a uranium extraction company positioning itself as "America's Clean Energy Company," saw its stock plummet 46% on Mar. 3, 2025, following a series of troubling disclosures. The NASDAQ-listed firm (EU) reported a net loss of $61.3 million for 2024, more than double the $25.6 million loss recorded in 2023. In a surprising turn of events, enCore also announced the abrupt departure of its Chief...
2025-03-12 2:56 PM EDT
AppLovin Corporation (APP) Faces Securities Class Action After Losing Over $14 Billion Of Shareholder Value - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 12, 2025) - A securities class action lawsuit, captioned Quiero v. AppLovin Corporation, et al., No. 4:25-cv-02294 (N.D. Cal.), has been filed. The suit seeks to represent investors who purchased AppLovin securities between May 10, 2023 and February 25, 2025. The suit follows the publication of two adverse short seller reports on February 26, 2025 that drove the price of AppLovin (NASDAQ: APP) shares sharply lower that day. Hagens Berman is...
2025-03-12 2:49 PM EDT
XYZ DEADLINE ALERT: Block, Inc. (XYZ) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 18th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - March 12, 2025) - Investors in Block, Inc. (NYSE: SQ) n/k/a (NYSE: XYZ) began to learn of potentially adverse information about the company and its Square and Cash App platforms on Mar. 23, 2023, when Hindenburg Research published a scathing report on the company. After a 2-year investigation, which included dozens of interviews with former employees, partners, and industry experts, Hindenburg concluded, in part, that Block had "wildly overstated...
2025-03-12 2:40 PM EDT
REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - March 7, 2025) - Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the company misled investors about its pricing practices for its blockbuster drug Eylea. The lawsuit, filed in the Southern District of New York, seeks to represent investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024. Hagens Berman urges investors who purchased...
2025-03-07 7:08 PM EST
TransMedics Group (TMDX) Faces Class-Action Suit Over Alleged Fraud and Safety Lapses- Hagens Berman
San Francisco, California--(Newsfile Corp. - March 6, 2025) - A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), represents investors who purchased or acquired TransMedics securities between February...
2025-03-06 1:51 PM EST
Atkore Inc. (ATKR) Faces Class Action Suit Over Potential Improper Revenues Recorded Pursuant to Anticompetitive Conduct - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 6, 2025) - A class action lawsuit has been filed against Atkore Inc. (NYSE: ATKR), a prominent manufacturer of electrical products, which include metal electrical conduit and fittings, plastic pipe conduit and fittings, electrical cable and flexible conduit, and international cable management systems. The suit, captioned Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Atkore Inc., et al., No. 1:25-cv-01851 (N.D....
2025-03-06 1:43 PM EST
Manhattan Associates (MANH) Faces Securities Class Action After $4 Billion of Shareholder Value Was Erased - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 4, 2025) - A class action lawsuit has been filed against Manhattan Associates, Inc. (NASDAQ: MANH), a global company that develops, sells, deploys, services, and maintains software solutions for the purpose of assisting in the management of supply chains, inventory, and omnichannel operations for its customers. The suit, captioned Prime v. Manhattan Associates, Inc., et al., No. 1:25-cv-00992-TRJ (N.D. Ga.), represents investors who purchased...
2025-03-04 10:17 AM EST
Semtech Corporation (SMTC) Faces Class Action Suit Over Alleged CopperEdge(TM) Misrepresentations - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 4, 2025) - A class action lawsuit has been filed against Semtech Corporation (NASDAQ: SMTC), a prominent high-performance, semiconductor, Internet of Things systems and cloud connectivity service provider, alleging that the company misled investors about the suitability of- and the ramp-up schedule for- its CopperEdge™ product portfolio. The suit, captioned Kleovoulos v. Semtech Corporation, et al., No. 2:25-cv-01474 (C.D. Cal.), represents...
2025-03-04 10:14 AM EST
Block, Inc. (XYZ) Faces Securities Class Action, Regulators Levy Cash App Fines Following Investigations Going Back to Hindenburg Report- Hagens Berman
San Francisco, California--(Newsfile Corp. - March 4, 2025) - Investors in Block, Inc. (NYSE: SQ) n/k/a (NYSE: XYZ) began to learn of potentially adverse information about the company and its Square and Cash App platforms on Mar. 23, 2023, when Hindenburg Research published a scathing report on the company. After a 2-year investigation, which included dozens of interviews with former employees, partners, and industry experts, Hindenburg concluded, in part, that Block had "wildly overstated...
2025-03-04 10:11 AM EST
Trade Desk (TTD) Faces Class Action Suit Over Alleged Kokai Rollout Stumbles - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 4, 2025) - A class action lawsuit has been filed against The Trade Desk, Inc. (NASDAQ: TTD), a prominent advertising technology firm, alleging that the company and certain executives engaged in fraudulent practices related to the company's rollout of Kokai, a generative artificial intelligence forecasting tool that enables users to more effectively deploy advertising spend. The suit, captioned United Union of Roofers, Waterproofers & Allied...
2025-03-04 10:10 AM EST
BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - March 4, 2025) - BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial. The biotech firm is pivoting to a preclinical neuroinflammation program, according to a recent company disclosure. This decision follows a securities class action lawsuit alleging BioAge made misleading statements and omissions related to its September 2024 initial public offering. The IPO...
2025-03-04 10:07 AM EST
Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices- Hagens Berman
San Francisco, California--(Newsfile Corp. - March 3, 2025) - Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the company misled investors about its pricing practices for its blockbuster drug Eylea. The lawsuit, filed in the Southern District of New York, seeks to represent investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024. Hagens Berman urges investors who purchased...
2025-03-03 3:32 PM EST
FTAI Aviation Ltd. (FTAI) Dismisses Short-Sellers' Allegations Without Providing Rebuttal Details, Questions Remain Amid Investor Lawsuit - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 27, 2025) - FTAI Aviation Ltd. (NASDAQ: FTAI) saw its shares jump on Feb. 20, after the aerospace firm dismissed allegations made by activist short-sellers Muddy Waters and Snowcap Research as "without merit." While the company's Audit Committee concluded that the claims lacked foundation, FTAI failed to provide specific rebuttals to detailed claims raised by Muddy Waters and a second short seller, Snowcap. FTAI's broad dismissal of the...
2025-02-27 1:49 PM EST
BIOA DEADLINE ALERT: BioAge Labs (BIOA) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - February 27, 2025) - BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial. The biotech firm is pivoting to a preclinical neuroinflammation program, according to a recent company disclosure. This decision follows a securities class action lawsuit alleging BioAge made misleading statements and omissions related to its September 2024 initial public offering. The...
2025-02-27 1:44 PM EST
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 27, 2025) - Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for EYLEA®, a key product. The firm pointed to preannounced January figures for the drug's sales. This downgrade...
2025-02-27 1:42 PM EST
TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 27, 2025) - A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), represents investors who purchased or acquired TransMedics securities between...
2025-02-27 1:32 PM EST
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 21, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm's attorneys. Class...
2025-02-21 1:43 PM EST
Crocs, Inc. (CROX) Faces Securities Class Action over HEYDUDE Pipeline - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 21, 2025) - Investors in Crocs, Inc. (NASDAQ: CROX) suffered yet another loss on Oct. 29, 2024 after the company prepared investors for disappointing Q4 and FY 2024 financial results that, in turn, sent shares crashing $26.47 (-19%). According to the company, the culprit was its HEYDUDE operating segment performance. Now a class action lawsuit has been filed focused on the propriety of Crocs' disclosures about sales practices within its...
2025-02-21 1:41 PM EST
Cardlytics (CDLX) Faces Investor Lawsuit Over Growth Projections - Hagens Berman
San Francisco, California--(Newsfile Corp. - February 20, 2025) - Cardlytics, the advertising technology company that connects marketers with consumers through their banking apps, is facing a class-action lawsuit alleging that it misled investors about its growth prospects. Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to...
2025-02-20 3:43 PM EST
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman
San Francisco, California--(Newsfile Corp. - February 20, 2025) - Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for EYLEA®, a key product. The firm pointed to preannounced January figures for the drug's sales. This downgrade...
2025-02-20 3:40 PM EST